Literature DB >> 23752730

Targeted therapies: Any surprises from selective oestrogen-receptor modulators?

V Craig Jordan1.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23752730     DOI： 10.1038/nrclinonc.2013.94

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  11 in total

Review 1.  Selective estrogen receptor modulation: concept and consequences in cancer.

Authors:  V Craig Jordan
Journal:  Cancer Cell       Date:  2004-03       Impact factor: 31.743

2.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Authors:  Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Scott M Lippman; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark
Journal:  JAMA       Date:  2006-06-05       Impact factor: 56.272

Review 3.  Chemoprevention of breast cancer with selective oestrogen-receptor modulators.

Authors:  V Craig Jordan
Journal:  Nat Rev Cancer       Date:  2007-01       Impact factor: 60.716

4.  Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.

Authors:  Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark
Journal:  Cancer Prev Res (Phila)       Date:  2010-04-19

5.  Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers.

Authors:  T Fornander; L E Rutqvist; B Cedermark; U Glas; A Mattsson; C Silfverswärd; L Skoog; A Somell; T Theve; N Wilking
Journal:  Lancet       Date:  1989-01-21       Impact factor: 79.321

Review 6.  Tamoxifen: a most unlikely pioneering medicine.

Authors:  V Craig Jordan
Journal:  Nat Rev Drug Discov       Date:  2003-03       Impact factor: 84.694

7.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

Authors:  B Fisher; J P Costantino; D L Wickerham; C K Redmond; M Kavanah; W M Cronin; V Vogel; A Robidoux; N Dimitrov; J Atkins; M Daly; S Wieand; E Tan-Chiu; L Ford; N Wolmark
Journal:  J Natl Cancer Inst       Date:  1998-09-16       Impact factor: 13.506

8.  A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer.

Authors:  T J Powles; J R Hardy; S E Ashley; G M Farrington; D Cosgrove; J B Davey; M Dowsett; J A McKinna; A G Nash; H D Sinnett
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

Review 9.  Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.

Authors:  Jack Cuzick; Ivana Sestak; Bernardo Bonanni; Joseph P Costantino; Steve Cummings; Andrea DeCensi; Mitch Dowsett; John F Forbes; Leslie Ford; Andrea Z LaCroix; John Mershon; Bruce H Mitlak; Trevor Powles; Umberto Veronesi; Victor Vogel; D Lawrence Wickerham
Journal:  Lancet       Date:  2013-04-30       Impact factor: 79.321

Review 10.  The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice.

Authors:  Philipp Y Maximov; Theresa M Lee; V Craig Jordan
Journal:  Curr Clin Pharmacol       Date:  2013-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.